Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the closing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering were $67.5 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have a 30-day option to purchase up to 675,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares in the offering were offered by Aquestive Therapeutics. The shares commenced trading on the Nasdaq Global Market on July 25, 2018 under the ticker symbol "AQST."
BMO Capital Markets and RBC Capital Markets acted as joint book-running managers for the offering. Wedbush PacGrow and JMP Securities acted as co-lead managers for the offering.
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

